Clinical Trials Logo

Clinical Trial Summary

Empagliflozin was recommended for patients with heart failure with reduced ejection fraction (HFrEF) in 2021 European Society of Cardiology (ESC) guidelines (Class of Recommendation Ia) and patients with heart failure with preserved ejection fraction (HFpEF) in 2022 American Heart Association (AHA) guidelines (Class of Recommendation IIa). However, the physiopathologic mechanisms in its effects on HFpEF are not clear. Studies illustrate that gut microbiota plays an essential role in the progress of the heart failure. Studies on mice found that sodium-glucose cotransporter-2 inhibitors (sglt-2i) could affect the intestinal microbiota in mice. The purpose of this study is to clarify the changes of gut microbiota in the patients with HFpEF taking Empagliflozin and explore the role of gut microbiota in this process.


Clinical Trial Description

As one of the most important cardiovascular diseases, heart failure is characterized by high incidence and high fatality rate. Heart failure with reduced ejection fraction (HFrEF) has been widely researched for decades and its clinical treatments have been improved remarkably. However, patients with non-reduced ejection fraction accounts for more than 50% of the whole group, especially patients with HFpEF. As for its complicated mechanism as well as normally less serious symptoms, its clinical treatments were not detailed enough before. Patients with heart failure often have decreased cardiac output combined with peripheral circulation congestion, leading to intestinal ischemia and edema. In this case, the intestinal barrier function is weakened, the intestinal wall permeability increases, the bacterial flora is displaced, and more harmful metabolites would also enter the blood circulation through the weakened intestinal mucosal barrier, inspiring more inflammatory substances and aggravating the states of heart failure. Empagliflozin is a sodium-glucose transporter 2 (sglt-2) inhibitor, which can inhibit the reabsorption of glucose in the kidney, discharge excessive glucose from the urine, and reduce blood glucose. It is a new type of hypoglycemic drugs. However, as the study progressed, the effect of sglt-2 inhibitors extends. In fundamental and animal trials, sglt-2 inhibitors were found to reduce sodium uptake, inhibit NO synthesis, improve cardiac energy metabolism, and inhibit cardiac inflammation. In the 2021 ESC heart failure guidelines, sglt-2 inhibitors have been included in the "new quadruple" therapy to target patients with HFrEF. Moreover, in the newly published EMPEROR-preserved study, Empagliflozin still achieved very good efficacy in ejection fraction-preserved heart failure, reducing the composite endpoint event by 21%. The mechanisms by which sglt-2 inhibitors act on heart failure have not been fully resolved, and in basic studies, sglt-2 inhibitors were found to affect the intestinal microbiota in mice. Based on the emerging importance of intestinal microbiota in the process of heart failure, and the impacts of sglt-2 inhibitors on intestinal microbiota and heart failure. It is necessary to clarify the changes of gut microbiota in the patients with non-reduced ejection fraction taking Empagliflozin and explore the role of gut microbiota in this process. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05584319
Study type Interventional
Source Shengjing Hospital
Contact
Status Enrolling by invitation
Phase Phase 4
Start date December 15, 2022
Completion date October 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy